Search results

Oxford BioMedica Receives Funding Award from the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study

-- Award of US$125,000 will support a second clinical site in Paris, France --

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-receives-funding-award-foundation-fighting-blindness

Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Colorectal Cancer

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-initiation-phase-ii-collaborative-study-trovax-0

Oxford BioMedica Announces Notice of Posting of Prospectus

Click here to view the prospectus

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-notice-posting-prospectus

Oxford BioMedica Announces US$3 million Option Exercise Payment from Sanofi

-- Sanofi acquires exclusive worldwide rights to develop and commercialise StarGen™ and UshStat® --

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-us3-million-option-exercise-payment-sanofi

Oxford BioMedica Announces Proposed Firm Placing of £11 million and Open Offer of up to £5 million

Click here to read

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-proposed-firm-placing-%C2%A311-million-and-open-offer

Oxford BioMedica Announces Successful MHRA Inspection for its Proprietary Manufacturing Facility

-- MHRA approval received to enable GMP manufacturing for clinical supply --

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-successful-mhra-inspection-its-proprietary

Oxford BioMedica Interim Management Statement May 2012

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-interim-management-statement-may-2012

Oxford BioMedica Announces Successful Completion of ProSavin® Phase I/II Study in Parkinson's Disease

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-successful-completion-prosavin%C2%AE-phase-iii-study

Oxford BioMedica Plc Preliminary Results for the Year Ended 31 December 2011

Click here 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-plc-preliminary-results-year-ended-31-december-2011

Oxford BioMedica Announces Successful Completion of ProSavin® Phase I/II Study in Parkinson's Disease

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-successful-completion-prosavin%C2%AE-phase-iii-0

Pages